Article
A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.
British journal of haematology - 1 Dec 2013
Grinfeld Jacob, Gerrard Gareth, Alikian Mary, Alonso-Dominguez Juan, Ale Sakuntala, Valgañon Mikel, Nteliopoulos Georgios, White Deborah, Marin David, Hedgley Corinne, O'Brien Stephen, Clark Richard, Goldman John M, Milojkovic Dragana, Apperley Jane F, Foroni Letizia
Abstract excerpt
Approximately one-third of patients with chronic myeloid leukaemia will fail to achieve or maintain responses to imatinib. Changes in solute carrier family 22 (organic cation transporter), member 1 (SLC22A1, also termed OCT1), the main transporter for imatinib, have been proposed as a possible predictive factor. We analysed SLC22A1 mRNA levels and single nucleotide polymorphisms (SNPs) located in exon 7 in 153...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.